Eli Lilly is stepping further into oncology with an agreement to acquire closely held Ajax Therapeutics for up to $2.3 billion in cash, a ...

Eli Lilly (NYSE:LLY) agreed to acquire Ajax Therapeutics for up to $2.3b, adding a Type II JAK2 inhibitor program for ...

Total consideration reaches up to $2.3 billion via upfront payment plus milestones tied to predefined clinical and regulatory ...

Eli Lilly and Company (NYSE: LLY) and Ajax Therapeutics, Inc. ("Ajax"), a biopharmaceutical company developing next ...

After the money Manchester United spent on the likes of Anthony and Donny van de Beek, it seemed unlikely that the side would ...

Eli Lilly to acquire Ajax Therapeutics for up to $2.3B, boosting blood cancer pipeline with a Phase 1 JAK2 inhibitor for ...

Lilly will pay up to $2.3B for Ajax and its AJ1‑11095 myelofibrosis drug; proof‑of‑concept data expected in 2026.

"We are off to a strong start this year, delivering $28.4 million in ACV, a 12% increase compared to Q1 last year" (CEO, President & Director Ramy Farid), while adding that "Drug discovery revenue of ...

In a world where the Power Four is relying more on Group of Five players, G5 teams should get transfers fees for developing ...

The acquisition is the latest in a series of recent deals that Indianapolis-based Eli Lilly and Co. has made to increase its cancer-treatment pipeline.

Ajax deal expands Lilly’s oncology pipeline; Hematology focus adds depth beyond GLP therapies; Healthcare strategy gains ...

Earn these JavaScript certs to demonstrate mastery of the most in-demand skills for the world’s most-used programming ...